Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring

Abstract

Background. Personalised medicine in oncology needs standardised immunological assays. Flow cytometry (FCM) methods represent an essential tool for immunomonitoring, and their harmonisation is crucial to obtain comparable data in multicentre clinical trials. The objective of this study was to design a harmonisation workflow able to address the most effective issues contributing to intraand interoperator variabilities in a multicentre project. Methods. The Italian National Institute of Health (Istituto Superiore di Sanità, ISS) managed a multiparametric flow cytometric panel harmonisation among thirteen operators belonging to five clinical and research centres of Lazio region (Italy). The panel was based on a backbone mixture of dried antibodies (anti-CD3, anti-CD4, anti-CD8, anti-CD45RA, and anti-CCR7) to detect naïve/memory T cells, recognised as potential prognostic/predictive immunological biomarkers in cancer immunotherapies. The coordinating centre distributed frozen peripheral blood mononuclear cells (PBMCs) and fresh whole blood (WB) samples from healthy donors, reagents, and Standard Operating Procedures (SOPs) to participants who performed experiments by their own equipment, in order to mimic a real-life scenario. Operators returned raw and locally analysed data to ISS for central analysis and statistical elaboration. Results. Harmonised and reproducible results were obtained by sharing experimental set-up and procedures along with centralising data analysis, leading to a reduction of crosscentre variability for naïve/memory subset frequencies particularly in the whole blood setting. Conclusion. Our experimental and analytical working process proved to be suitable for the harmonisation of FCM assays in a multicentre setting, where high-quality data are required to evaluate potential immunological markers, which may contribute to select better therapeutic options.

Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications

“…The underlying principle using pre-formulated, single tube antibody cocktails, makes these assays a promising method for the standardized monitoring of CAR-T immunotherapy and therefore has also been suggested by others ( 31 , 32 ). The DURAclone technology used here has been successfully applied for the detection of regulatory T cells (Tregs), naïve/memory T cells and other immune cells in the peripheral blood of healthy human donors in previous work ( 33 – 35 ). Furthermore, the feasibility of this technology for immuno-monitoring of cancer patients has been proven by the detection of minimal residual disease (MRD) in myeloma patients and by analyzing blood cells of cancer patients in response to immunotherapeutic nanoparticles ( 36 , 37 ).…”

Interlaboratory comparison of high-throughput protein biomarker assay quantifications for radiation exposure classification

“…Important to this work, we developed a master template for analyzing biomarker % Positive values generated from harmonized ISX instruments, removing the need for instrument-specific analysis templates and calibration curves. Subjective gating differences at each site may contribute to readout variability and the centralization of the data analysis with a master template removes individualized gating methods, which can cause interlaboratory variation [ 9 , 13 ]. Should samples be prepared and/or analyzed at other sites, a more complete validation of bioassay reproducibility and harmonization of other sources of variability will also be required.…”

Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring

“…Immunomonitoring has become increasingly relevant in the many medical fields. In immuno-oncology it is used for the identification of potential prognostic or predictive immune biomarkers and a better understanding of their underlying mechanisms of action, leading to improved personalized treatments [ 31 ]. In addition, the SARS-CoV-2 pandemic that emerged in late 2019 revealed the necessity of a rapid and simple immunomonitoring method.…”